Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Share:
Related REGN
Lightning Round: Jim Cramer Shares His Thoughts On GameStop, Pfizer And More
Neothetics' Fat Reduction Candidate Fails in Phase II Study
The Best- and Worst-Performing Stocks of the Last Decade (GuruFocus)
Related AGN
Top Stock Reports for Oracle, Allergan & Abbott
Benzinga's Top Upgrades, Downgrades For June 16, 2017
Cedar Wealth Management, LLC Buys Vanguard Total International Stock ETF, Vanguard Short-Term ... (GuruFocus)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Jul 2017Morgan StanleyMaintainsEqual-Weight
Jun 2017BernsteinDowngradesOutperformMarket Perform
May 2017Canaccord GenuityUpgradesHoldBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

View Comments and Join the Discussion!